New Zealand markets close in 3 hours 31 minutes

Revvity, Inc. (RVTY)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
111.61+1.57 (+1.43%)
At close: 04:00PM EDT
111.61 0.00 (0.00%)
After hours: 06:25PM EDT

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees11,000

Key executives

NameTitlePayExercisedYear born
Dr. Prahlad R. Singh Ph.D.CEO, President & Director1.43MN/A1965
Mr. Maxwell KrakowiakSenior VP & CFO631.11kN/A1990
Mr. Tajinder S. VohraSenior Vice President of Global Operations574.08kN/A1966
Mr. Joel S. GoldbergSenior VP of Administration, General Counsel & Secretary720.74kN/A1969
Ms. Miriame VictorSenior VP & Chief Commercial Officer555.4kN/A1982
Mr. Andrew OkunVP, Chief Accounting Officer & TreasurerN/AN/A1970
Mr. Bryan A. KippSenior Vice President of Technology & LicensingN/AN/AN/A
Ms. Madhuri Hegde FACMG, Ph.D.Senior VP & Chief Scientific OfficerN/AN/AN/A
Mr. Stephen Barr WilloughbySenior VP of Investor Relations & Head of ESGN/AN/AN/A
Ms. Magali FourSenior VP and Chief People & Culture OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate governance

Revvity, Inc.’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.